Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12166948rdf:typepubmed:Citationlld:pubmed
pubmed-article:12166948lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12166948lifeskim:mentionsumls-concept:C0038454lld:lifeskim
pubmed-article:12166948lifeskim:mentionsumls-concept:C0872271lld:lifeskim
pubmed-article:12166948lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:12166948lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:12166948lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:12166948lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:12166948pubmed:issue17lld:pubmed
pubmed-article:12166948pubmed:dateCreated2002-8-8lld:pubmed
pubmed-article:12166948pubmed:abstractTextWe have synthesized a series of 6,7-benzomorphan derivatives and determined their ability to bind to voltage-dependent sodium channels. We have also compared the functional consequences of this blockade in vitro and in vivo. The ability of the compounds to displace [(3)H]batrachotoxin from voltage-dependent sodium channels was compared with their ability to inhibit [(3)H]glutamate release in rat brain slices and block convulsions in the maximal electroshock test in mice. We found that the hydroxyl function in the 4'-position is crucial for improving the sodium channel blocking properties. Moreover, the stereochemistry and the topology of the N-linked side chain also influence this interaction. Indeed, the affinity is improved by an aromatic substitution in the side chain. By modifying the N substituent and the substitution pattern of the hydroxyl function, we were able to discover (2R)-[2alpha,3(S),6alpha]-1,2,3,4,5,6-hexahydro-6,11,11-tri-methyl-3-[2-(phenylmethoxy)propyl]-2,6-methano-3-benzazocin-10-ol hydrochloride. This compound was chosen as the best candidate for further pharmacological investigations.lld:pubmed
pubmed-article:12166948pubmed:languageenglld:pubmed
pubmed-article:12166948pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:citationSubsetIMlld:pubmed
pubmed-article:12166948pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12166948pubmed:statusMEDLINElld:pubmed
pubmed-article:12166948pubmed:monthAuglld:pubmed
pubmed-article:12166948pubmed:issn0022-2623lld:pubmed
pubmed-article:12166948pubmed:authorpubmed-author:NarHerbertHlld:pubmed
pubmed-article:12166948pubmed:authorpubmed-author:WeiserThomasTlld:pubmed
pubmed-article:12166948pubmed:authorpubmed-author:GrauertMatthi...lld:pubmed
pubmed-article:12166948pubmed:authorpubmed-author:BechtelWolf...lld:pubmed
pubmed-article:12166948pubmed:authorpubmed-author:StranskyWerne...lld:pubmed
pubmed-article:12166948pubmed:authorpubmed-author:CarterAdrian...lld:pubmed
pubmed-article:12166948pubmed:issnTypePrintlld:pubmed
pubmed-article:12166948pubmed:day15lld:pubmed
pubmed-article:12166948pubmed:volume45lld:pubmed
pubmed-article:12166948pubmed:ownerNLMlld:pubmed
pubmed-article:12166948pubmed:authorsCompleteYlld:pubmed
pubmed-article:12166948pubmed:pagination3755-64lld:pubmed
pubmed-article:12166948pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:meshHeadingpubmed-meshheading:12166948...lld:pubmed
pubmed-article:12166948pubmed:year2002lld:pubmed
pubmed-article:12166948pubmed:articleTitleSynthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.lld:pubmed
pubmed-article:12166948pubmed:affiliationDepartment of Medicinal Chemistry, Boehringer Ingelheim Pharma KG, 88397 Biberach an der Riss, and Corporate Development, Boehringer Ingelheim GmbH, 55216 Ingelheim am Rhein, Germany. Matthias.Grauert@bc.boehringer-ingelheim.comlld:pubmed
pubmed-article:12166948pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12166948pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:12166948lld:chembl